In this study, we aimed to investigate whether high parathormone (PTH) levels in obese patients contribute to the metabolic complications of obesity.
Methods:
A total of 400 obese subjects aged 18–65 years were included. Anthropometric bioelectrical bioimpedance measures, blood tests, and 75 gram oral glucose tolerance test results were evaluated.
Results:
Of the 400 obese subjects, 335 were female. The mean age was 39 ± 10 years. The median body mass index was 36 (interquartile range 34–41). Subjects were divided into quartiles according to blood PTH levels. Groups included quartile 1 [n = 100, median PTH; 42 (range 36–45)], quartile 2 [n = 100, median PTH; 55 (51–59)], quartile 3 [n = 100, median PTH; 73 (68–78)], and quartile 4 [n = 100, median PTH; 99 (89–125)]. Quartiles were evaluated with a generalized linear model adjusted for age, sex, and season of recruitment. Systolic and diastolic blood pressure, fasting glucose, homeostatic model assessment-estimated insulin resistance, insulin sensitivity index, triglyceride level, and high-density lipoprotein cholesterol (HDL-C) were not different among quartiles. PTH and 25 hydroxyvitamin D (25(OH)D) were not associated with higher odds of prevalent metabolic syndrome in obese subjects (odds ratio, OR, 0.99 [95% confidence interval, CI, 0.981.00], P = 0.38 and 0.99 95% CI 0.96–1.01], P = 0.46, respectively). Decreased 25(OH)D levels were significantly correlated with higher odds of low HDL-C (OR 0.96 [95% CI 0.93–0.99], P = 0.04).
Conclusions:
PTH does not contribute to the occurrence of metabolic components of obesity, but there is a positive correlation between 25(OH)D and HDL-C.
Get full access to this article
View all access options for this article.
References
1.
ReisJP, von MühlenD, MillerER3rd. Relation of 25-hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur J Endocrinol, 2008; 159:41–48.
2.
ReisJP, von MühlenD, Kritz-SilversteinD, et al.Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care, 2007; 30:1549–1555.
3.
HagströmE, LundgrenE, LithellH, et al.Normalized dyslipidaemia after parathyroidectomy in mild primary hyperparathyroidism: Population-based study over five years. Clin Endocrinol (Oxf), 2002; 56:253–260.
4.
ChiuKC, ChuangLM, LeeNP, et al.Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level. Metabolism, 2000; 49:1501–1505.
5.
ProcopioM, MagroG, CesarioF, et al.The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed Type 2 diabetes mellitus in primary hyperparathyroidism. Diabet Med, 2002; 19:958–961.
6.
van BallegooijenAJ, ReindersI, VisserM, et al.Serum parathyroid hormone in relation to all-cause and cardiovascular mortality: The Hoorn study. J Clin Endocrinol Metab, 2013; 98:E638–E645.
7.
HagströmE, AhlströmT, ÄrnlövJ, et al.Parathyroid hormone and calcium are independently associated with subclinical vascular disease in a community-based cohort. Atherosclerosis, 2015; 238:420–426.
8.
BuizertPJ, van SchoorNM, SimsekS, et al.PTH: A new target in arteriosclerosis?. J Clin Endocrinol Metab, 2013; 98:E1583–E1590.
9.
Pereira-SantosM, CostaPR, AssisAM, et al.Obesity and vitamin D deficiency: A systematic review and meta-analysis. Obes Rev, 2015; 17.
10.
BollandMJ, GreyAB, GambleGD, et al.Association between primary hyperparathyroidism and increased body weight: A meta-analysis. J Clin Endocrinol Metab, 2005; 90:1525–1530.
11.
AdamMA, UntchBR, DankoME, et al.Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J Clin Endocrinol Metab, 2010; 95:4917–4924.
12.
PitrodaAP, HarrisSS, Dawson-HughesB. The association of adiposity with parathyroid hormone in healthy older adults. Endocrine, 2009; 36:218–223.
13.
McCartyMF, ThomasCA. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis-implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypotheses, 2003; 61:535–542.
14.
KamychevaE, SundsfjordJ, JordeR. Serum parathyroid hormone level is associated with body mass index. The 5th Tromsø study. Eur J Endocrinol, 2004; 151:167–172.
15.
ChristensenMH, DankelSN, NordbøY, et al.Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue. PLoS One, 2011; 6:e20481.
16.
SukumarD, PartridgeNC, WangX, et al.The high serum monocyte chemoattractant protein-1 in obesity is influenced by high parathyroid hormone and not adiposity. J Clin Endocrinol Metab, 2011; 96:1852–1858.
17.
HoutkooperLB, LohmanTG, GoingSB, et al.Why bioelectrical impedance analysis should be used for estimating adiposity. Am J Clin Nutr, 1996; 64:436S–448S.
18.
Lloret LinaresC, CianguraC, BouillotJL, et al.Validity of leg-to-leg bioelectrical impedance analysis to estimate body fat in obesity. Obes Surg, 2011; 21:917–923.
19.
MatsudaM, DeFronzoRA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care, 1999; 22:1462–1470.
20.
MatthewsDR, HoskerJP, RudenskiAS, et al.Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412–419.
21.
International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Accessed at www.idf.org/metabolic-syndrome on February2, 2015.
22.
KocełakP, ChudekJ, Olszanecka-GlinianowiczM. Prevalence of metabolic syndrome and insulin resistance in overweight and obese women according to the different diagnostic criteria. Minerva Endocrinol, 2012; 37:247–254.
23.
HjelmesaethJ, HofsøD, AasheimET, et al.Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: A cross-sectional study. Cardiovasc Diabetol, 2009; 8:7.
24.
GuaschA, BullóM, RabassaA, et al.Plasma vitamin D and parathormone are associated with obesity and atherogenic dyslipidemia: A cross-sectional study. Cardiovasc Diabetol, 2012; 11:149.
25.
RuedaS, Fernández-FernándezC, RomeroF, et al.Vitamin D, PTH, and the metabolic syndrome in severely obese subjects. Obes Surg, 2008; 18:151–154.
26.
KimH, KalkhoffRK, CostriniNV, et al.Plasma insulin disturbances in primary hyperparathyroidism. J Clin Invest, 1971; 50:2596–2605.
27.
PragerR, KovarikJ, SchernthanerG, et al.Peripheral insulin resistance in primary hyperparathyroidism. Metabolism, 1983; 32:800–805.
28.
TassoneF, ProcopioM, GianottiL, et al.Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism. Diabet Med, 2009; 26:968–973.
29.
TaylorWH, KhaleeliAA. Prevalence of primary hyperparathyroidism in patients with diabetes mellitus. Diabet Med, 1997; 14:386–389.
30.
KhaleeliAA, JohnsonJN, TaylorWH. Prevalence of glucose intolerance in primary hyperparathyroidism and the benefit of parathyroidectomy. Diabetes Metab Res Rev, 2007; 23:43–48.
31.
AlemzadehR, KichlerJ. Parathyroid hormone is associated with biomarkers of insulin resistance and inflammation, independent of vitamin D status, in obese adolescents. Metab Syndr Relat Disord, 2012; 10:422–429.
32.
TaylorWH, KhaleeliAA. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev, 2001; 17:175–180.
33.
TemizkanS, KocakO, AydinK, et al.Normocalcemic hyperparathyroidism and insulin resistance. Endocr Pract, 2015; 21:23–29.
34.
BelliaA, MarinoniG, D'AdamoM, et al.Parathyroid hormone and insulin resistance in distinct phenotypes of severe obesity: A cross-sectional analysis in middle-aged men and premenopausal women. J Clin Endocrinol Metab, 2012; 97:4724–4732.
35.
HagströmE, LundgrenE, RastadJ, et al.Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol, 2006; 155:33–39.
36.
PondaMP, HuangX, OdehMA, et al.Vitamin D may not improve lipid levels: A serial clinical laboratory data study. Circulation, 2012; 126:270–277.
37.
Boonchaya-anantP, HolickMF, ApovianCM. Serum 25-hydroxyvitamin D levels and metabolic health status in extremely obese individuals. Obesity,- 2014; 22:2539–2543.
38.
YagiS, AiharaK, KondoT, et al.High serum parathyroid hormone and calcium are risk factors for hypertension in Japanese patients. Endocr J, 2014, 61:727–733.
39.
van BallegooijenAJ, KestenbaumB, SachsMC, et al.Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol, 2014; 63:1214–1222.
40.
KimH, ChungYE, JungSC, et al.Independent associations of circulating 25-hydroxyvitamin D and parathyroid hormone concentrations with blood pressure among Koreans: The Korea National Health and Nutrition Examination Survey (KNHANES), 2009–2010. Calcif Tissue Int, 2013; 93:549–555.
41.
FischerE, HannemannA, RettigR, et al.A high aldosterone to renin ratio is associated with high serum parathyroid hormone concentrations in the general population. J Clin Endocrinol Metab, 2014; 99:965–971.
